UNSPSC 51292017: Talopram

This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PY881HC79, chemically known as 3,3-dimethyl-1-(3-methylaminopropyl)-1-phenylphthalene but generally known as talopram, which bears US NIH Compound Identifier 23573. European Medicines Agency schedules Talopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10811MIG.

UNSPSC 51292017 Talopram is a Commodity code that encompasses pharmaceutical products, specifically branded and generic medications procured by state and local health agencies, public health departments, and cooperative purchasing alliances to support community health initiatives, pharmacy benefit programs, and emergency response efforts. State and local governments buying under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing consortiums that coordinate procurement across multiple jurisdictions and authorized pharmaceutical wholesalers. The work involves sourcing medications with specific National Drug Codes (NDCs), certifying compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintaining contractual relationships with authorized wholesalers, and fulfilling delivery schedules tied to community health facilities or pharmacy benefit networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026, and awarded vendors effective July 1, 2026.